RECOMBINANT INTERFERON-ALPHA-2B IN THE MANAGEMENT OF MALIGNANT PLEURAL EFFUSIONS

Authors
WILKINS HE CONNOLLY MM GRAYS P MARQUEZ G NELSON D
Citation
He. Wilkins et al., RECOMBINANT INTERFERON-ALPHA-2B IN THE MANAGEMENT OF MALIGNANT PLEURAL EFFUSIONS, Chest, 111(6), 1997, pp. 1597-1599
Citations number
17
Categorie Soggetti
Respiratory System
Journal title
Chest → ACNP
ISSN journal
00123692
Volume
111
Issue
6
Year of publication
1997
Pages
1597 - 1599
Database
ISI
SICI code
0012-3692(1997)111:6<1597:RIITMO>2.0.ZU;2-C
Abstract
Twenty-one patients with malignant pleural effusion (MPE) were prospec tively entered into a nonrandomized, single-armed study to evaluate th e efficacy and safety of recombinant interferon (IFN) alpha-2b (INTRON A; Schering-Plough; Kenilworth, NJ) as an intrapleural palliative age nt. From March 1989 through February 1993 (48 months), 21 patients wer e entered into the study. No symptomatic effusion recurred and no subs tantial side effects were associated with treatment. This suggests rec ombinant IFN alpha-2b represents a safe and effective intrapleural age nt for the palliation of MPE.